Skip to content
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe
12Jan2026
  • Home
  • About
  • News
  • Subscribe
12Jan2026
Cost Curve NewsCost Curve News
Cost Curve News

A ‘Most-Favored Nation’ Approach in Medicaid Would Have Mammoth Unintended Consequences

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

APEX | ‘Most-Favored Nation’ Is Floated by the White House … to a Frosty Reception from Congress

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
8 months ago
Keep Reading
Cost Curve News

APEX | Obesity Grabs the Headlines: Looking at a Novo Formulary Win and a New Paper on Budget Impact

Premium Content This content is reserved for premium subscribers of Premium Membership. To Access this and other great posts, consider upgrading to premium. UpgradeLink ConjuctionSign In Powered by beehiiv  
9 months ago
Keep Reading
Cost Curve News

Earnings Calls Are Chockablock With Policy Talk This Month: MFN, PBMs, 340B, and More

BENDING YOUR EAR/ Cost Curve Apex Launches Tomorrow Cost Curve Apex -- the premium version of this newsletter -- launches tomorrow with the goal of ensuring I’m providing the best
9 months ago
Keep Reading
Cost Curve News

Novo and Telehealth Companies Team Up in the Next Turn of the Pharm-to-Table Story

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
9 months ago
Keep Reading
Cost Curve News

Thoughts on an Arnold Ventures-Backed Poll on ‘Negotiations’ That Fails to Account for Access/Innovation Tradeoffs

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
9 months ago
Keep Reading
Cost Curve News

Digging Even Deeper Into the Treasure Trove of the Cassidy Report on 340B

Thing I learned yesterday: Shel Silverstein wrote “A Boy Named Sue.” I had no idea. REBOUND (1)/ More Cassidy 340B Reactions, More Cassidy 340B Angles I was one of those
9 months ago
Keep Reading
Cost Curve News

Senate Report on 340B Rams Home a Simple Message: The Program Is Broken

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
9 months ago
Keep Reading
Cost Curve News

More Evidence that the IRA’s Warped Incentives Are Reducing Research

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
9 months ago
Keep Reading
Cost Curve News

More Details on How the Administration’s New-Look 340B Program Might Operate

If you want to search Cost Curve back issues or link to anything you read here, the web links and archive are online at costcurve.beehiiv.com. You can subscribe there, too.
9 months ago
Keep Reading
161718

Latest Posts

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

January 9, 2026

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

January 8, 2026

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

January 7, 2026

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

January 6, 2026

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

January 5, 2026

Popular

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

Empty Offices, Full Coffers: A Journalistic Expose Examines How PBMs Use Group Purchasing Organizations to Profit

The Most Interesting Drug Pricing News of the Year Is Flying Under the Radar

We’re Back at It. Here Are the Four Key Holiday Storylines to Get You Caught Up.

Happy Festivus! Cost Curve Readers Have Some Grievances They’d Like to Air.

Most Viewed
  • CMS Patient-Focused Listening Session Transcripts (3,074)
  • New JAMA Research Shows How Much — and How Rapidly — Part D Plans Have Shifted Drug Costs to Consumers (2,265)
  • Working Out the Strange Math and Weird Consequences of IRA Inflation Penalties (2,015)
  • More IRA Lawsuits Coming, PhRMA Chief Predicts (1,825)
  • Bernie Sanders Wants to Talk to CEOs About US vs ROW Pricing. Bring It On, I Say. (1,816)

Your trusted source for daily updates on drug pricing and policy. Stay informed and ahead of the curve with Cost Curve News.

Latest News

J&J Becomes Company No. 15 to Make a Deal with the White House, Though Details Remain Sparse

January 9, 2026

Will Pharma’s MFN Deals to Change the Drug-Price Reality for U.S. Patients or European Governments?

January 8, 2026

Subcribe To Newsletter

Subscribe to our newsletter and stay informed about new posts and stay up-to-date on the latest news
Subscribe
© 2026 Cost Curve News | All Rights Reserved
Cost Curve NewsCost Curve News
  • Home
  • About
  • News
  • Subscribe